Microparticles as new markers of cardiovascular risk in diabetes and beyond

Summary

The term microparticle (MP) identifies a heterogeneous population of vesicles playing a relevant role in the pathogenesis of vascular diseases, cancer and metabolic diseases such as diabetes mellitus. MPs are released by virtually all cell types by shedding during cell growth, proliferation, activation, apoptosis or senescence processes. MPs, in particular platelet- and endothelial-derived MPs (PMPs and EMPs), are increased in a wide range of thrombotic disorders, with an interesting relationship between their levels and disease pathophysiology, activity or progression. EMP plasma levels have been associated with several cardiovascular diseases and risk factors. PMPs are also shown to be involved in the progressive formation of atherosclerotic plaque and development of arterial thrombosis, especially in diabetic patients. Indeed, diabetes is characterised by an increased procoagulant state and by a hyperreactive platelet phenotype, with enhanced adhesion, aggregation, and activation. Elevated MP levels, such as TF⁺ MPs, have been shown to be one of the procoagulant determinants in patients with type 2 diabetes mellitus. Atherosclerotic plaque constitutes an opulent source of sequestered MPs, called “plaque” MPs. Otherwise, circulating MPs represent a TF reservoir, named “blood-borne” TF, challenging the dogma that TF is a constitutive protein expressed in minute amounts. “Blood-borne” TF is mainly harboured by PMPs, and it can be trapped within the developing thrombus. MP detection and enumeration by polychromatic flow cytometry (PFC) have opened interesting perspectives in clinical settings, particularly for the evaluation of MP numbers and phenotypes as independent marker of cardiovascular risk, disease and outcome in diabetic patients.

Keywords

Microparticles - atherosclerosis - tissue factor - platelet - diabetes

• References

• 1 Shantsila E. et al. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358-2368.
• 2 Montoro-Garcia S. et al. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 2011; 106: 911-923.
• 3 Gyorgy B. et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-2688.
• 4 Wu ZH. et al. Membrane microparticles and diseases. Eur Rev Med Pharmacol Sci 2013; 17: 2420-2427.
• 5 Jaiswal R. et al. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One 2013; 8: e61515.
• 6 Sabatier F. et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51: 2840-2845.
• 7 Sinning JM. et al. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32: 2034-2041.
• 8 Burger D. et al. Microparticles: biomarkers and beyond. Clin Sci 2013; 124: 423-441.
• 9 Wojta J.. Platelet-derived microparticles in patients with high cardiovascular risk and subclinical atherosclerosis. Thromb Haemost 2015; 114: 1099.
• 10 Davi G, Ferroni P.. Microparticles in type 2 diabetes mellitus. J Thromb Haemost 2005; 3: 1166-1167.
• 11 Leroyer AS. et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49: 772-777.
• 12 Zhang X. et al. Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis 2014; 37: 455-463.
• 13 Tramontano AF. et al. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm 2010; 2010: 250476.
• 14 Davi G, Patrono C.. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 15 Orbe J. et al. Matrix metalloproteinase-10 is upregulated by thrombin in endothelial cells and increased in patients with enhanced thrombin generation. Arterioscler Thromb Vasc Biol 2009; 29: 2109-2116.
• 16 Davi G. et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
• 17 Davi G. et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterialdisease. Circulation 1997; 96: 69-75.
• 18 Mallat Z. et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
• 19 Bernal-Mizrachi L. et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-970.
• 20 Min PK. et al. Circulating Microparticles and Coronary Plaque Components Assessed by Virtual Histology Intravascular Ultrasound of the Target Lesion in Patients with Stable Angina. PLoS One 2016; 11: e0148128.
• 21 Romano M. et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care 2001; 24: 1674-1678.
• 22 van der Pol E. et al. Innovation in detection of microparticles and exosomes. J Thromb Haemost 2013; 11 (Suppl. 01) 36-45.
• 23 Lacroix R. et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardisation of protocol. J Thromb Haemost 2012; 10: 437-446.
• 24 Horstman LL. et al. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135.
• 25 Lee TH. et al. Microvesicles as mediators of intercellular communication in cancer–the emerging science of cellular 'debris'. Semin Immunopathol 2011; 33: 455-467.
• 26 Lacroix R. et al. Standardisation of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
• 27 Yuana Y. et al. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011; 105: 396-408.
• 28 Lee RD. et al. Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 2012; 129: 80-85.
• 29 Ayers L. et al. Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res 2011; 127: 370-377.
• 30 Stagnara J. et al. Correlation between platelet-derived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: the centrifugation step matters!. Thromb Haemost 2012; 107: 1185-1187.
• 31 Dignat-George F. et al. Centrifugation is a crucial step impacting microparticle measurement. Platelets 2009; 20: 225-226 author reply 227-228.
• 32 Shah MD. et al. Flow cytometric measurement of microparticles: pitfalls and protocol modifications. Platelets 2008; 19: 365-372.
• 33 Dey-Hazra E. et al. Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 2010; 6: 1125-1133.
• 34 Chandler WL.. Microparticle counts in platelet-rich and platelet-free plasma, effect of centrifugation and sample-processing protocols. Blood Coagul Fibrinolysis 2013; 24: 125-132.
• 35 Chattopadhyay PK. et al. A chromatic explosion: the development and future of multiparameter flow cytometry. Immunology 2008; 125: 441-449.
• 36 Lawrie AS. et al. Microparticle sizing by dynamic light scattering in fresh-frozen plasma. Vox Sang 2009; 96: 206-212.
• 37 Chandler WL. et al. A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer. J Thromb Haemost 2011; 9: 1216-1224.
• 38 Gyorgy B. et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood 2011; 117: e39-48.
• 39 Larson MC. et al. Calcium-phosphate microprecipitates mimic microparticles when examined with flow cytometry. Cytometry A 2013; 83: 242-250.
• 40 Lanuti P. et al. A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction. J Immunol Methods 2012; 380: 16-22.
• 41 Larson MC. et al. Circulating membrane-derived microvesicles in redox biology. Free Radic Biol Med 2014; 73: 214-228.
• 42 Piedras-Ross J. et al. Comparison of single- and dual-platform approaches to enumerate CD34(+) cells in bone marrow and mobilized peripheral blood stem cells. Arch Med Res 2003; 34: 16-19.
• 43 Zampetaki A. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
• 44 Nomura S. et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995; 116: 235-240.
• 45 Rautou PE. et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593-606.
• 46 Tricot O. et al. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 2000; 101: 2450-2453.
• 47 Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 27-33.
• 48 Dean WL. et al. Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost 2009; 102: 711-718.
• 49 Barry OP. et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-2127.
• 50 Montoro-Garcia S. et al. Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin. Br J Haematol 2014; 166: 571-580.
• 51 Mause SF. et al. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005; 25: 1512-1518.
• 52 Forlow SB. et al. Leukocyte-leukocyte interactions mediated by platelet micro-particles under flow. Blood 2000; 95: 1317-1323.
• 53 Mallat Z. et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-353.
• 54 Morel O. et al. Procoagulant microparticles: disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
• 55 Distler JH. et al. The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis 2005; 10: 731-741.
• 56 Silverstein RL.. Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress. Clin Lipidol 2009; 4: 767.
• 57 Vasina EM. et al. Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis 2011; 2: e211.
• 58 Pakala R. Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc Radiat Med 2004; 5: 20-26.
• 59 Postea O. et al. Contribution of platelet CX(3)CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler Thromb Vasc Biol 2012; 32: 1186-1193.
• 60 Sarkar A. et al. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One 2009; 4: e7140.
• 61 Brisset AC. et al. Shedding of active tissue factor by aortic smooth muscle cells (SMCs) undergoing apoptosis. Thromb Haemost 2003; 90: 511-518.
• 62 Martinez de Lizarrondo S. et al. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol 2012; 32: 1477-1487.
• 63 Leroyer AS. et al. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularisation. J Am Coll Cardiol 2008; 52: 1302-1311.
• 64 Mause SF.. Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis. Thromb Haemost 2013; 109: 5-6.
• 65 Nomura S.. Microparticle and Atherothrombotic Diseases. J Atheroscler Thromb 2016; 23: 1-9.
• 66 Aharon A. et al. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008; 100: 878-885.
• 67 De Meyer GR. et al. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res 2002; 90: 1197-1204.
• 68 Amabile N. et al. Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. Eur Heart J 2014; 35: 2972-2979.
• 69 Mobarrez F. et al. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One 2014; 9: e90314.
• 70 Ferreira AC. et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation 2004; 110: 3599-3603.
• 71 Naghavi M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-1778.
• 72 Nozaki T. et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54: 601-608.
• 73 Werner N. et al. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 112-116.
• 74 Bulut D. et al. CD31+/Annexin V+ microparticles in healthy offsprings of patients with coronary artery disease. Eur J Clin Invest 2009; 39: 17-22.
• 75 Bulut D. et al. Circulating endothelial microparticles correlate inversely with endothelial function in patients with ischaemic left ventricular dysfunction. J Card Fail 2008; 14: 336-340.
• 76 Viera AJ. et al. Microparticles in cardiovascular disease pathophysiology and outcomes. J Am Soc Hypertens 2012; 6: 243-252.
• 77 Habersberger J. et al. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res 2012; 96: 64-72.
• 78 Suades R. et al. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. Int J Cardiol 2015; 202: 378-387.
• 79 Chalimoniuk M. et al. Diversity of endurance training effects on antioxidant defenses and oxidative damage in different brain regions of adolescent male rats. J Physiol Pharmacol 2015; 66: 539-547.
• 80 Suades R. et al. Growing thrombi release increased levels of CD235a(+) micro-particles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients. J Thromb Haemost 2015; 13: 1776-1786.
• 81 Min PK. et al. Local increase in microparticles from the aspirate of culprit coronary arteries in patients with ST-segment elevation myocardial infarction. Atherosclerosis 2013; 227: 323-328.
• 82 Biasucci LM. et al. Differences in microparticle release in patients with acute coronary syndrome and stable angina. Circ J 2012; 76: 2174-2182.
• 83 Jung C. et al. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis 2012; 221: 226-231.
• 84 Switonska M. et al. Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation. Eur J Neurol 2015; 22: 395-401 e28-29.
• 85 Simak J. et al. Circulating endothelial microparticles in acute ischaemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost 2006; 4: 1296-1302.
• 86 Jung KH. et al. Circulating endothelial microparticles as a marker of cerebrovascular disease. Ann Neurol 2009; 66: 191-199.
• 87 Lee ST. et al. Circulating CD62E+ microparticles and cardiovascular outcomes. PLoS One 2012; 7: e35713.
• 88 Kuriyama N. et al. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin Appl Thromb Hemost 2010; 16: 26-32.
• 89 Chen Y. et al. The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischaemic Stroke Patients. J Stroke Cerebrovasc Dis. 2015 Epub ahead of print.
• 90 Nomura S. et al. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost 2004; 10: 205-215.
• 91 Berezin AE. et al. Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus. J Endocrinol Invest 2015; 38: 865-874.
• 92 Diamant M. et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
• 93 Morel O. et al. Endothelial cell activation contributes to the release of procoagulant microparticles during acute cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 38-45.
• 94 Chironi GN. et al. Endothelial microparticles in diseases. Cell Tissue Res 2009; 335: 143-151.
• 95 Stec JJ. et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102: 1634-1638.
• 96 Santilli F. et al. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13: 27-42.
• 97 Zhang X. et al. Oat-enriched diet reduces inflammatory status assessed by circulating cell-derived microparticle concentrations in type 2 diabetes. Mol Nutr Food Res 2014; 58: 1322-1332.
• 98 Patrono C. et al. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005; 5: 198-203.
• 99 Ishida K. et al. Circulating microparticles from diabetic rats impair endothelial function and regulate endothelial protein expression. Acta Physiol 2016; 216: 211-220.
• 100 Jansen F. et al. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res 2013; 98: 94-106.
• 101 Curtis AM. et al. Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. Cytometry B Clin Cytom 2010; 78: 329-337.
• 102 Heinrich LF. et al. Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells. Br J Nutr 2015; 113: 1704-1711.
• 103 Tushuizen ME. et al. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost 2006; 4: 1003-1010.
• 104 Vajen T. et al. Microvesicles from platelets: novel drivers of vascular inflammation. Thromb Haemost 2015; 114: 228-236.
• 105 Mobarrez F. et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352.
• 106 Koga H. et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45: 1622-1630.
• 107 Jung KH. et al. Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles. Cerebrovasc Dis 2011; 31: 485-493.
• 108 Tsimerman G. et al. Involvement of microparticles in diabetic vascular complications. Thromb Haemost 2011; 106: 310-321.
• 109 Feng B. et al. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 2010; 208: 264-269.
• 110 Nomura S. et al. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets 2009; 20: 406-414.
• 111 Koga H. et al. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J 2006; 27: 817-823.
• 112 Lumsden NG. et al. Endothelial dysfunction in patients with type 2 diabetes post acute coronary syndrome. Diab Vasc Dis Res 2013; 10: 368-374.
• 113 Bernard S. et al. Increased levels of endothelial microparticles CD144 (VE- Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis 2009; 203: 429-435.
• 114 Chen Y. et al. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens 2012; 14: 455-460.
• 115 Diehl P. et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 2012; 93: 633-644.
• 116 Chen J. et al. Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischaemic damage. Am J Physiol Endocrinol Metab 2011; 301: E62-71.
• 117 Mohler 3rd ER. et al. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A 2009; 75: 75-82.
• 118 Dimmeler S. et al. HMG- Co A reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397.
• 119 Zhang Y. et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133-144.
• 120 Matsumoto S. et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 2013; 113: 322-326.
• 121 Jy W. et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1842-1851.
• 122 Qiao JL. et al. Proteolysis of platelet receptors in humans and other species. Biol Chem 2010; 391: 893-900.
• 123 Wu CC. et al. A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 2003; 21: 532-538.
• 124 Xu Y. et al. Novel test for microparticles in platelet-rich plasma and platelet concentrates using dynamic light scattering. Transfusion 2011; 51: 363-370.
• 125 Varga Z. et al. Towards traceable size determination of extracellular vesicles. J Extracell Vesicles 2014; 3
• 126 Parot P. et al. Past, present and future of atomic force microscopy in life sciences and medicine. J Mol Recognit 2007; 20: 418-431.
• 127 Simonsen JB.. A liposomal-based size calibration method for measuring microvesicles by flow cytometry. J Thromb Haemost. 2015 Epub ahead of print.
• 128 Ueba T. et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008; 100: 280-285.
• 129 Reverter JC. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and „clinical restenosis”. J Clin Invest 1996; 98: 863-874.
• 130 Tramontano AF. et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004; 320: 34-38.
• 131 Nomura S. et al. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 133-141.
• 132 Morel O. et al. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003; 1: 171-177.
• 133 Baron M. et al. Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?. J Cell Mol Med 2012; 16: 1365-1376.